The DOI matches its Crossref record.
Treatment of primary pulmonary hypertension intravenous epoprostenol (prostacyclin).
Open accessAbstract
Ten patients with severe primary pulmonary hypertension and pronounced disability who were unresponsive to oral vasodilators were treated with intravenous epoprostenol (prostacyclin). All had been referred for heart and lung transplantation. Short term administration of epoprostenol (mean dose 5.5 ng/kg/min) increased the mean cardiac index from 1.8 to 2.2 1/min/m2, improved pulmonary artery oxygen saturation from 48% to 57%, and increased calculated tissue oxygen delivery from 10 to 11.8 ml/kg/min. The mean pulmonary vascular resistance fell by 18% while mean systemic artery pressure fell by 32%. Pulmonary artery pressure rose in only two patients. Continued intravenous infusion of epoprostenol for 1-25 months was associated with subjective and clinical improvement. Exercise tolerance improved as measured by an increase in the maximum rate of oxygen consumption during progressive exercise testing. In those six patients who were able to exercise before treatment it rose from a mean of 7 to 15 ml/kg/min. Those who had been unable to exercise before treatment achieved comparable rates of oxygen consumption after treatment. Two patients died on treatment, three have undergone heart-lung transplantation, and in five the treatment is continuing. Complications included episodes of septicaemia and ascites. In this uncontrolled study of patients with severe pulmonary hypertension epoprostenol seemed to offer a means of optimally dosing the patients with a vasodilator to reduce pulmonary vascular resistance and thus increasing cardiac output and oxygen tissue delivery. There was no evidence to suggest that this treatment influenced the progress of the disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Regulatory Functions of the Vascular Endothelium
Epstein, F. H., Vane, J. R., Änggård, E. E., & Botting, R. M. (1990) · New England Journal of Medicine · doi:10.1056/nejm199007053230106 · Cited by 1,889
Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension
PEPKEZABA, J. (1991) · The Lancet · doi:10.1016/0140-6736(91)92033-x · Cited by 1,055
Rubin, L. J., Mendoza, J., Hood, M., McGoon, M., Barst, R., Williams, W. B., Diehl, J. H., Crow, J., & Long, W. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-112-7-485 · Cited by 706
Wensel, R., Opitz, C. F., Anker, S. D., Winkler, J., Höffken, G., Kleber, F. X., Sharma, R., Hummel, M., Hetzer, R., & Ewert, R. (2002) · Circulation · doi:10.1161/01.cir.0000022687.18568.2a · Cited by 567
Primary Pulmonary Hypertension
Rubin, L. J. (1993) · Chest · doi:10.1378/chest.104.1.236 · Cited by 305
Metadata
- Authors
- Jones, D. K., Higenbottam, T. W., & Wallwork, J.
- Venue
- Heart
- Publisher
- BMJ
- Published
- 1987-03-01
- Volume
- 57
- Issue
- 3
- Pages
- 270-278
- ISSN
- 1355-6037 (ISSN-L)
- OpenAlex
- W2142044870
- Cited by
- 161
- References
- 0
- FWCI
- 13.05
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment of primary pulmonary hypertension intravenous epoprostenol (prostacyclin). https://app.cochat.ai/papers/10.1136/hrt.57.3.270
- The paper
- Jones, D. K., Higenbottam, T. W., & Wallwork, J. (1987). Treatment of primary pulmonary hypertension intravenous epoprostenol (prostacyclin). Heart. https://doi.org/10.1136/hrt.57.3.270
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.